Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
German Court Rejects Bid To Force BMW and Mercedes-Benz To Stop Selling New Combustion-Engine Cars After 2030 - 2Brazil expands pesticide packaging reverse logistics
- 3Israeli strike on Gaza City vehicle kills at least four, report says
- 4'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- 5Help Your Insusceptibility: Good dieting and Way of life Tips
- South African army arrive in crime hotspots to help tackle gangs
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- Instructions to Perform Fundamental Upkeep on Your Slam 1500.
- 5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Ariana Grande to host 'Saturday Night Live' Christmas show with Cher as musical guest, returning after nearly 40 years
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- Dad issues urgent plea to find stem cell donor for his son
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
